A Phase IB/II Study Evaluating the Safety, Tolerability and Anti-Tumour Activity of Polatuzumab Vedotin (dcds4501a) in Combination with Rituximab or Obinutuzumab (g) plus Bendamustine (b) in Relapsed or Refractory Follicular or Diffuse Large b-cell Lymphoma

Project: Research

Project Description

NMA Reference Number: HREC/15/RAH/279
SSA Reference Number: SSA/15/MonH/213
Monash Health HREC Ref: 15557X
StatusActive
Effective start/end date27/05/1926/05/24

Keywords

  • clinical trial
  • treatment efficacy
  • lymphoma